The pharmacokinetics of VP16 have been investigated in Lewis lung bearing mice after i.v. doses of 13 and 40 mg/kg. At both doses the plasma elimination half-life was around 30 min. The lowest VP16-213 levels were in brain and primary tumor. Drug concentrations were much higher in metastases than in primary tumor. The highest concentrations were in small intestine, liver and kidney. Drug levels in the liver were disproportionally higher after 40 mg/kg, the AUC value being approximately 12 times greater than after 13 mg/kg. Urinary excretion of VP16-213 as unchanged drug accounted for 20–30% of the administered dose in the 60 h after treatment. The concentration cytotoxicity curve was very steep and apparently similar for cells derived from primary tumor or metastases grown in vitro.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Allen LM, Creaven PJ (1975) Comparison of human pharmacokinetics of VM26 and VP16, two antineoplastic epipodophyllotoxin glucopyranoside derivatives. Eur J Cancer 11:697
Cattan A, Pourny C, Carpentier Y, Cattan E, Barouh M (1976) Antimetastasis effect of two derivatives of epipodophyllotoxin in mice. Eur J Cancer 12:797
D'Incalci M, Farina P, Fasoli M, Marsoni S (1981) VP16 plasma levels after i.v. and two methods of oral administration to choriocarcinoma patients. Proc Am Soc Clin Oncol 22:357
Donelli MG, Colombo T, Broggini M, Garattini S (1977) Differential distribution of antitumoral agents in primary and secondary tumors. Cancer Treat Rep 61:1319
Farina P, Marzillo G, D'Incalci M (1981) High-performance liquid chromatography determination of 4′-demethylepi-podophyllotoxin-9-(4,6-o-ethylidene-β-d-glucopyranoside) (VP16-213) human plasma. J Chromatogr 222:141
Issell BF, Crooke ST (1979) Etoposide (VP16-213). Cancer Treat Rev 6:107
Nissen NI, Larsen V, Pedersen H, Thomsen K (1972) Phase I clinical trial of a new antitumor agent, 4′-demethylepipodo-phyllotoxin-9-(4,6-o-ethylidene-β-d-glucopyranoside) (NSC-141540; VP16-213). Cancer Chemother Rep 56:769
Rivera G, Avery T, Pratt C (1975) 4′-Demethylepipodophyllotoxin-9-(4,6-o-2-thenylidene-β-d-glucopyranoside) (NSC-122819; VM26) and 4′-demethylepipodophyllotoxin-9-(4,6-o-ethylidene-β-d-glucopyranoside) (NSC-141540; VP16-213) in childhood cancer: Preliminary observations. Cancer Chemother Rep 59:743
Rozencweig M, Van Hoff DD, Henney JE, Muggia FM (1977) VM26 and VP16-213: A comparative analysis. Cancer 40:334
Stähelin H (1973) Activity of a new glycosidic lignan derivative (VP16-213) related to podophyllotoxin in experimental tumors. Eur J Cancer 9:215
This work was partially supported by CNR Progetto Finalizzato No. 80.01593.96. The generous contribution of the Italian Association for Cancer Research, Milan, Italy, is gratefully acknowledged.
About this article
Cite this article
Colombo, T., Broggini, M., Torti, L. et al. Pharmacokinetics of VP16-213 in Lewis lung carcinoma bearing mice. Cancer Chemother. Pharmacol. 7, 127–131 (1982). https://doi.org/10.1007/BF00254534
- Primary Tumor
- Small Intestine
- Drug Concentration
- Urinary Excretion